The Dubai-based company offers a range of therapeutic products, including CLASTEON for bone metastasis, SANCUSO for chemotherapy-induced nausea and vomiting, and GLICONORM for non-insulin dependent diabetes mellitus. Newbridge Pharmaceuticals serves biotechnology and pharmaceutical companies in the Middle East, Africa, Turkey, and Caspian Regions, with a focus on addressing unmet medical needs in the MENA region for diseases such as cancer, diabetes, renal and cardiovascular diseases, and other metabolic disorders. Founded in 2007, the company is committed to providing patients with effective treatments for critical diseases.